Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix's REZZAYO Phase III Trial Hits Primary Endpoint for Fungal Prophylaxis, Targets $2B Market Expansion

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$7.471
Mkt Cap
$581.936M
52W Low
$6.125
52W High
$17.43
52W Position info
22% above low
Off High info
57% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CRMD sits 22% above its 52-week low of $6.125.

Summary

CorMedix Therapeutics announced positive topline results from its Phase III ReSPECT trial for REZZAYO, demonstrating non-inferiority against standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients. The study successfully met its primary endpoint for fungal-free survival at Day 90, and REZZAYO showed a favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions. This outcome significantly expands the potential market for REZZAYO, with CorMedix estimating the US prophylaxis market opportunity to exceed $2 billion. The company plans a pre-NDA meeting with the FDA in the coming months, targeting a supplemental New Drug Application (sNDA) submission in the second half of 2026, which will be a key catalyst for the stock.

At the time of this announcement, CRMD was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $581.9M. The 52-week trading range was $6.13 to $17.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $5.30 info
Change: -$0.200 (-4%) info
Market Cap: $413.105M info
CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.30 info
Change: -$0.200 (-4%) info
Market Cap: $413.105M info
CRMD
Nov 02, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.62
Real-time Price: $5.30 info
Change: -$0.3155 (-6%) info
Market Cap: $413.105M info
CRMD
Oct 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $5.30 info
Change: -$2.15 (-29%) info
Market Cap: $413.105M info
CRMD
Aug 13, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $5.30 info
Change: -$2.35 (-31%) info
Market Cap: $413.105M info